

1 **TERRA transcription destabilizes telomere integrity to initiate break-induced replication**
2 **in human ALT cells.**

3

4 Bruno Silva^{1,3}, Rajika Arora^{1,2,3} and Claus M. Azzalin^{1,4,*}

5

6

7 ¹Instituto de Medicina Molecular João Lobo Antunes (iMM), Faculdade de Medicina da
8 Universidade de Lisboa, Lisbon, Portugal

9

10 ²Present address: Institute for Molecular Health Sciences, ETHZ, Zürich, Switzerland

11

12 ³These authors contributed equally

13

14 ⁴Lead Contact

15

16 *Correspondence: cmazzalin@medicina.ulisboa.pt

17

18 **ABSTRACT**

19 Alternative Lengthening of Telomeres (ALT) is a Break-Induced Replication (BIR)-based
20 mechanism elongating telomeres in a subset of human cancer cells. While the notion that
21 spontaneous DNA damage at telomeres is required for ALT to occur, the molecular
22 triggers of this physiological telomere instability are largely unknown. We previously
23 proposed that the telomeric long noncoding RNA TERRA may represent one such trigger;
24 however, given the lack of tools to suppress TERRA transcription in cells, our hypothesis
25 remained speculative. We have now developed Transcription Activator-Like Effectors able
26 to rapidly inhibit TERRA transcription from multiple chromosome ends in an ALT cell line.
27 TERRA transcription inhibition decreases marks of DNA replication stress and DNA
28 damage at telomeres and impairs ALT activity and telomere length maintenance. We
29 conclude that TERRA transcription actively destabilizes telomere integrity in ALT cells,
30 thereby initiating BIR and supporting telomere elongation. Our data point to TERRA
31 transcription manipulation as a potentially useful target for therapy.

32

33 INTRODUCTION

34 Transcription of telomeric DNA into the long noncoding RNA TERRA is an evolutionarily
35 conserved feature of eukaryotic cells with linear chromosomes¹. RNA polymerase II
36 produces TERRA proceeding from subtelomeric regions towards chromosome ends and
37 using the C-rich telomeric strand as a template. As a result, TERRA molecules comprise
38 chromosome-specific subtelomeric sequences followed by a variable number of
39 telomeric UUAGGG repeats²⁻⁴. TERRA is found either dispersed throughout the
40 nucleoplasm or associated with telomeric chromatin, as well as other genomic loci that
41 contain or not telomeric DNA repeats⁴⁻⁷. The molecular mechanisms mediating TERRA
42 retention on chromosomes still need to be fully elucidated; however, the propensity of
43 TERRA to form RNA:DNA hybrids with its template DNA strand (telomeric R-loops or telR-
44 loops)⁸⁻¹¹ and the physical interaction of human TERRA with the shelterin factors TRF1
45 and TRF2^{12,13} suggest that TERRA association with telomeric DNA-containing loci involves
46 RNA/DNA and RNA/protein interactions.

47 The chromosomal origin of human TERRA is controversial. Using RT-PCR and
48 Illumina sequencing, independent laboratories reported on the existence of TERRA
49 molecules originating from a multitude of chromosome ends^{3,14-19}. Consistently, we
50 previously identified CpG dinucleotide-rich tandem repeats of 29 bp displaying promoter
51 activity and located on approximately half of chromosome ends². 29 bp repeats are
52 positioned at variable distances from the first telomeric repeat and their transcriptional
53 activity is repressed by CpG methylation². Moreover, transcription factor binding sites
54 exist on multiple subtelomeres and inactivation of some of them alter TERRA levels in
55 cells^{14,20-22}. However, work from the Blasco laboratory, based on reanalysis of TERRA
56 Illumina sequencing and molecular and cell biological validation experiments, posed that
57 human TERRA is mainly transcribed from one unique locus on the long arm of the
58 chromosome 20 (20q) subtelomere^{23,24}. The same group used CRISPR/Cas9 to delete a
59 8.1 kb fragment from the 20q subtelomere comprising 4 putative promoters in U2OS
60 osteosarcoma cells and isolated several clonal lines (20q-TERRA KO cells). Seemingly

61 supporting the proposed origin of TERRA, 20q-TERRA KO cells displayed substantially
62 diminished total TERRA levels when compared to parental cells^{23,24}.

63 TERRA is involved in several telomere-associated processes including telomerase
64 recruitment and regulation, telomeric DNA replication, telomeric heterochromatin
65 establishment, response to DNA damage at telomeres and replicative senescence
66 establishment¹. Our laboratory and others have implicated TERRA also in telomere
67 elongation in telomerase-negative cancer cells with an activated Alternative Lengthening
68 of Telomeres (ALT) mechanism^{8,9,24,25}. ALT is a specialized pathway repairing and thus re-
69 elongating damaged telomeres through Break-Induced Replication (BIR) occurring in the
70 G2 and M phases of the cell cycle and requiring the DNA polymerase delta accessory
71 subunits POLD3 and POLD4²⁵⁻²⁹. Consistent with a function for TERRA in ALT, human ALT
72 cells, including U2OS, are characterized by elevated telomeric transcription and TERRA
73 levels, in part owed to hypomethylation of 29/37 repeats, and abundant telR-loops^{2,8,15}.
74 Moreover, the RNA:DNA endoribonuclease RNaseH1 and the ATPase/helicase FANCM
75 dismantle telomeric R-loops and FANCM restricts total TERRA levels specifically in ALT
76 cells. Because RNaseH1 and FANCM inactivation increases telomere instability and ALT
77 activity, while their over-expression alleviates ALT^{8,9,30,31}, we proposed that a
78 physiological damage triggered by TERRA/telR-loops at ALT telomeres may provide the
79 substrate for BIR-mediated telomere elongation^{8,9,32,33}. However, due to a lack of tools to
80 rapidly suppress TERRA transcription in cells, our hypothesis remained speculative.
81 Further challenging our hypothesis, 20q-TERRA KO cells show increased telomeric
82 localization of the DNA damage factors γ H2AX and 53BP1 and telomeric fusions²⁴, which
83 has been interpreted as evidence for TERRA capping, rather than destabilizing, telomeres
84 in ALT cells.

85

86 RESULTS

87 Development of Transcription Activator-Like Effectors binding to 29 bp repeats.

88 To assess the short-term impact of TERRA transcription on telomere stability in ALT cells
89 we engineered Transcription Activator-Like Effectors (TALEs)³⁴ targeting a 20 bp sequence
90 within the 29 bp repeat consensus² (herein referred to as T-TALEs; Fig. 1a). Variable
91 numbers of exact 20 bp sequences are found within the last 3 kb of 20 different
92 subtelomeres (3p, 5p, 9p, 12p, 16p, 19p, 1q, 2q, 4q, 5q, 6q, 10q, 11q, 13q, 15q, 16q, 19q,
93 21q, 22q, and Xq/Yq). T-TALEs were C-terminally fused to a strong nuclear localization
94 signal (NLS), four transcription repressor domains of the mSIN3 interaction domain
95 (Enhanced Repressor Domain, SID4X) and a human influenza hemagglutinin (HA) epitope
96 (Fig. 1a). T-TALEs not fused to SID4X were used as controls. Transgenes were cloned
97 downstream of a doxycycline (dox) inducible promoter and stably integrated into U2OS
98 cells expressing the tetracycline repressor protein. Several clonal cell lines were isolated
99 in absence of dox and successively tested for dox-induced T-TALE expression by western
100 blot and indirect immunofluorescence (IF) using anti-HA antibodies. Two independent cell
101 lines for SID4X-fused T-TALEs (sid1 and sid4) and two for unfused T-TALEs (nls1 and nls3)
102 were chosen for further experiments because: i) transgene expression was almost
103 undetectable in absence of dox; and ii) dox treatments induced expression of ectopic
104 proteins homogeneously distributed across the cell population, properly localized to the
105 nucleus and at fairly similar levels in the four cell lines (Fig. 1a, S1a and b).

106 To confirm T-TALE binding specificity, we treated nls3, sid4 and parental U2OS
107 cells with dox for 24 hours and performed chromatin immunoprecipitations (ChIPs) with
108 anti-HA antibodies followed by qPCR using oligonucleotide amplifying subtelomeric
109 sequences from several chromosome ends either containing or not 29 bp repeat
110 sequences (29 bp+ and 29 bp-, respectively). DNA in very close proximity of 29 bp repeats
111 on chromosomes 10q, 15q and XYq subtelomeres was enriched in nls3 and sid4 ChIP
112 samples over parental U2OS samples. The enrichment diminished for sequences more
113 distant from the 29 bp repeats on the same subtelomeres (Fig. 1b). On the contrary, no
114 enrichment was observed for DNA from 29 bp- subtelomeres (XYp and 12q), the

115 centromere of the X chromosome, centromeric alphoid repeats and the beta Actin or U6
116 gene loci (Fig. 1b). This confirms that T-TALEs specifically bind to 29 bp repeat.

117

118 **T-TALEs rapidly suppress TERRA transcription from 29 bp repeat-containing**
119 **chromosome ends.**

120 To test the functionality of T-TALEs, we treated cells with dox for 24 hours and performed
121 RT-qPCR to measure TERRA levels from 29 bp+ (9Xq, 10q, 15q and 16p) and 29 bp- (10p,
122 12q, 20q and XYp) subtelomeres. In sid1 and sid4 cells, TERRA from 29 bp+ subtelomeres
123 was greatly reduced while TERRA from 29 bp- was not affected. In nls1 and 3 cells, no
124 significant change in TERRA levels was observed at any chromosome ends (Fig. 1c).
125 Fluorescence-activated cell sorting (FACS) of propidium iodide (PI)-stained cells did not
126 reveal cell cycle profile alterations in dox-treated nls and sid cells as compared to
127 untreated controls (Fig. S2a and b); this indicates that the TERRA decrease observed in
128 sid1 and sid4 cells is not an indirect consequence of a disturbed cell cycle progression.
129 Further supporting this notion, in ALT cells, TERRA levels do not diminish when the cell
130 cycle progresses from S to G2 phases, as typical in telomerase positive cells^{4,35}. Hence,
131 our TALE-based system can efficiently and specifically inhibit TERRA transcription from 29
132 bp promoter repeats. Notably, because TERRA transcription from 29 bp- chromosome
133 ends is not affected in dox-treated sid cells, an immediate cross-talk between the
134 transcriptional state of independent telomeres appears not to exist in U2OS cells.
135 However, a larger number of ends would need to be tested to corroborate this conclusion.

136

137 **TERRA transcription suppression alleviates telomere instability.**

138 To probe the effects of TERRA transcription inhibition on telomere stability, we performed
139 indirect immunofluorescence (IF) using antibodies against the single-stranded DNA
140 binding protein RPA32, RPA32 phosphorylated at serine 33 (pSer33) or γ H2AX combined
141 with either telomeric DNA fluorescence in situ hybridization (FISH) or IF against the
142 shelterin component TRF2. RPA32 and pSer33 were used as markers of DNA replication
143 stress, while γ H2AX as a broad DNA damage marker. Dox treatments diminished the

144 telomeric localization of both RPA32 variants in *sid1* and *sid4* cells (Fig. 2a and b, Fig. S3)
145 already at 24 hours after drug delivery. A slightly sharper decrease was observed for total
146 RPA32 than for pSer33, suggesting that a fraction of the protein binds to telomeres
147 independently of serine 33 phosphorylation or that the protein undergoes
148 dephosphorylation while still telomere-bound. Similarly, dox treatments diminished the
149 frequencies of γ H2AX co-localization with telomeres in *sid1* and *sid4* cells (Fig. 2a and b,
150 Fig. S3). Dox treatments did not alter co-localization frequencies for any of the tested
151 markers in *nls1* and *nls3* cells (Fig. 2a and b, Fig. S3). Moreover, dox did not affect the
152 total cellular levels of RPA32, pSer33, γ H2AX and TRF2 nor did it impair RPA32 and H2AX
153 phosphorylation when cells were simultaneously treated with the damaging agent
154 camptothecin (Fig. S1b). Hence, all changes observed in dox-treated *sid1* and *sid4* cells do
155 not derive from altered protein cellular levels or from a compromised DNA damage
156 response. Alterations in cell cycle distribution also cannot account for the observed
157 changes in RPA32, pSer33 and γ H2AX at telomeres (Fig. S2a and b).

158

159 **TERRA transcription suppression inhibits ALT activity and telomere maintenance.**

160 According to our model, diminished telomere instability should weaken ALT activity. To
161 test this, we first quantified ALT-associated PML bodies (APBs) by combining IF with an
162 anti-PML antibody and telomeric DNA FISH. APBs diminished in *sid1* and *sid4* but not in
163 *nls1* and *nls3* cells already 24 hours after adding dox (Fig. 3a and b, Fig. S3). We then
164 synchronized cells at the G1/S transition and let them progress from S-phase to G2 in
165 presence of dox and the Cdk1 inhibitor RO-3306. Cells were pulsed with EdU during the
166 last 2.5 hours of treatment and subjected to EdU detection combined with telomeric DNA
167 FISH. Dox did not affect the frequencies of EdU co-localization with telomeric DNA in *nls1*
168 and *nls3* cells, while it substantially diminished them in *sid1* and *sid4* cells (Fig. 3a and b,
169 Fig. S3). This suggests that dox treatments reduced telomeric BIR in G2 synchronized
170 *sid* cells. Consistently, as shown by double IF experiments, dox diminished the frequencies
171 of POLD3 co-localization with the shelterin component RAP1 in *sid1* and *sid4*, but not in
172 *nls1* and *nls3* G2 cells (Fig. 3a and b, Fig. S3). Changes in APBs and POLD3 telomeric

173 localization occurred in absence of changes in PML, POLD3 and RAP1 total protein levels
174 (Fig. S1b). Moreover, dox treatments did not affect the efficiency of our synchronization
175 protocol (Fig. S2a and b). Thus, the decline in ALT features observed in *sid1* and *sid4* cells
176 cannot be ascribed to altered protein levels or differences in the fraction of cells in G2
177 phase.

178 As additional markers for ALT activity, we also quantified C-circles, which are
179 circular telomeric DNA molecules with exposed single stranded C-rich tracts, and
180 telomeric sister chromatid exchanges (TSCs)²⁶. C-circle assays with total genomic DNA
181 did not disclose consistent changes in *sid1*, *nls1* and *sid4* cells treated with dox for up to
182 72 hours. In *nls3* cells, C-circle levels diminished after 24 hours of treatment and started
183 to recover at later timepoints (Fig. S4a and b). Chromosome orientation FISH (CO-FISH)
184 on *nls3* and *sid4* metaphase chromosomes did not detect significant changes in TSC
185 frequencies associated with dox treatments in either cell line (Fig. 4a-c). However, we
186 noticed unequal distribution of leading and lagging strand signals at several chromosome
187 ends. Thus, we also quantified the occurrence of sister telomeres with 2 leading and one
188 lagging strand signals (double leading or DLead) and with 2 lagging and one leading strand
189 signals (double lagging or Dlagg). Dlagg telomeres were not affected by dox treatments
190 in both cell lines, while DLead telomeres were more than halved in *sid4* but not *nls3* dox-
191 treated cells as compared to untreated controls (Fig. 4a-c).

192 Alleviation of ALT activity should translate into impaired telomere elongation and
193 progressive loss of telomeric DNA. We treated cells with dox over a prolonged time course
194 and analyzed telomeres by telomeric DNA FISH on metaphase chromosomes. TERRA
195 transcription suppression in *sid1* and *sid4* cells was maintained throughout the entire
196 time course (data not shown). A progressive, statistically significant accumulation of
197 telomere free ends (TFEs) was observed in *sid1* and *sid4* cells treated with dox for up to
198 15 and 9 days, respectively (Fig. 5a and b). Conversely, no significant change in TFEs was
199 observed in *nls3* cells during the tested time course (Fig. 5a and b).

200

201 **DISCUSSION**

202 We have developed an efficient system to suppress TERRA transcription from several
203 chromosome ends in an ALT cell line. Importantly, rapid suppression of TERRA
204 transcription across a cell population provides the critical advantage to study the
205 immediate consequences on telomere homeostasis, avoiding secondary effects
206 associated with clonal selection and expansion after TERRA inhibition. Our data clearly
207 establish that TERRA transcription inhibition impairs accumulation of DNA instability
208 markers (RPA32 and γ H2AX) at telomeres, weakens ALT features (APBs and PLD3-
209 dependent synthesis of telomeric DNA in G2 cells) and causes TFE generation. We
210 propose that, in ALT cells, TERRA transcription is a major trigger of replication stress-
211 associated telomere instability and, in turn, BIR-mediated telomere elongation. The only
212 partial decrease in telomere instability and ALT activity observed in dox-treated *sid1* and
213 *sid4* cells is most likely explained by the fact that T-TALEs only target a subset of telomeres
214 and/or the existence of additional telomere instability triggers, for example G-quadruplex
215 structures²⁵. Based on previous studies on RNaseH1 and FANCM^{8,12} and the ability of R-
216 loops to induce DNA instability³⁶, it seems likely that TERRA transcription causes
217 replication stress by stalling the replication fork through telR-loop formation. It is also
218 possible that telomere instability derives from the collision between TERRA transcription
219 and telomeric replication forks. Importantly, our data argue against the notion that TERRA
220 caps ALT telomeres, as it was previously proposed based on the massive accumulation of
221 telomeric DNA damage in 20q-TERRA KO cells²⁴. On the contrary, TERRA transcription
222 actively destabilizes the integrity of ALT telomeres to support their elongation and cell
223 immortality. In our view, the telomeric DNA damage detected in U2OS 20q-TERRA KO
224 cells originates from the very short telomeres present in those cells and does not
225 underscore direct TERRA-associated capping functions²⁴.

226 It is interesting that not all tested ALT features, including C-circles, are affected
227 when TERRA transcription is inhibited. Two alternative BIR pathways have been shown to
228 co-exist in ALT cells, one RAD52-dependent and associated with C-circle production, and
229 the other RAD52-independent and not leading to C-circle production²⁹. It is possible that

230 TERRA only supports RAD52-independent BIR, although this hypothesis is not consistent
231 with the observed C-circle accumulation in RNaseH1- and FANCM-depleted ALT
232 cells^{8,9,30,31}. We thus consider that mild changes in C-circles upon partial TERRA
233 transcription inhibition may fall below the detection limit of our assays. TSCEs are also
234 not affected when TERRA transcription is inhibited. This observation was surprising
235 because 20q-TERRA KO cells are characterized by diminished TSCE frequencies²⁴.
236 However, a substantial fraction of the overall short telomeres in 20q-TERRA KO cells might
237 have escaped detection in CO-FISH experiments, thus skewing the results and their
238 interpretation. Regardless, our analysis in T-TALE cells revealed that TERRA transcription
239 promotes the formation of rearranged chromosome ends with leading strand replication
240 DNA present at both sisters (DLeads); hence, the mechanisms leading to TSCEs and
241 DLeads are different. Because TERRA transcription promotes telomeric BIR, we interpret
242 DLead structures as the outcome of premature termination of post-replicative BIR events
243 initiating with a lagging strand telomere invading a leading strand one from another
244 chromosome (Fig. 4d). As soon as a D-loop is formed, it could be resolved by structure-
245 specific endonucleases, for example the SMX complex, which has been previously
246 implicated in ALT³⁷⁻⁴¹. Endonucleolytic cleavage followed by end-joining would
247 translocate the distal part of the leading strand telomere onto the lagging strand one,
248 thus generating a DLead structure (Fig. 4d).

249 Events where lagging strand telomeres translocate onto leading strand ones,
250 thereby generating DLead ends, also seem to occur. However, because TERRA
251 transcription inhibition does not affect DLead frequencies, different molecular triggers
252 appear to act at leading and lagging strand telomeres to initiate BIR. The specificity of
253 TERRA transcription on DLead frequencies can be explained in two alternative, yet not
254 mutually exclusive ways. One possibility is that TERRA transcription increases the
255 propensity of lagging strand telomeres to invade other chromosome ends, for example
256 by inducing replication fork stalling and DSBs through telR-loop formation³⁶. Because telR-
257 loops, at least in budding yeast, are more abundant at short telomeres⁴², this might
258 constitute a regulatory mechanism directing ALT towards the shortest telomeres in the

259 cell. Alternatively, TERRA transcription could prime leading strand telomeres to act as
260 templates for BIR by altering their structure; this also could depend on the formation of
261 telR-loops, as they might shape the double helix into an ideal entry platform for an
262 annealing reaction involving a switch between TERRA and the 3' end of the acceptor
263 telomere. This second hypothesis is supported by the observation that, in ALT cells,
264 aberrant telR-loop accumulation due to RNaseH1 depletion causes rapid loss of leading
265 strand telomeres⁸.

266 Our findings also unmistakably settle that multiple chromosome ends, and not
267 only the one of 20q, are actively transcribed and further validate that the previously
268 identified 29 pb repeats are functional and physiologically relevant TERRA promoters².
269 We believe that the diminished levels of cellular UUAGGG repeats in 20q-TERRA KO
270 cells^{23,24} derive from the short telomeres in those cells and/or clonal variability, and thus
271 do not imply that 20q is the main TERRA locus in ALT cells. Moreover, although our T-
272 TALEs do not affect 20q-TERRA transcription, which is expected because the 20q
273 subtelomere does not contain 29 bp repeats, impaired telomere maintenance is observed
274 both in our system and in 20q-TERRA KO cells; this suggests that many if not all telomeres
275 in a cell have to stay transcriptionally active to assure proper ALT-mediated elongation.

276 Lastly, we anticipate that TERRA transcription might become a useful target for
277 therapy. The physiological instability of ALT telomeres has to be kept within a precise
278 range in order to trigger sufficient BIR yet without causing cell death³², implying that
279 TERRA transcription must also be controlled. Decreasing TERRA transcription, for example
280 through chemical inhibition of TERRA promoter activity, is expected to alleviate
281 replication stress and lead to inefficient elongation and, in the long term, cell proliferation
282 arrest. On the other hand, increasing TERRA transcription would generate excessive
283 telomere instability, which, if above cellular tolerance, could cause sudden cell death.
284 Modulating TERRA transcription holds the potential to spearhead unprecedented
285 therapeutic protocols in the fight against ALT cancers.

286

287 **ACKNOWLEDGMENTS**

288 We thank Harry Wischnewski for help with RT-qPCRs and C-circle assays, and the
289 Bioimaging and Flow Cytometry facilities of IMM for services. This work was supported by
290 the European Molecular Biology Organization (IG3576) and the Fundação para a Ciência
291 e a Tecnologia (IF/01269/2015; PTDC/MED-ONC/28282/2017; PTDC/BIA-
292 MOL/29352/2017).

293

294

295 **AUTHOR CONTRIBUTIONS**

296 R.A. and C.M.A. conceived the original project. B.S., R.A. and C.M.A designed and
297 performed the experiments, analyzed the data and wrote the manuscript.

298

299

300 **DECLARATION OF INTERESTS**

301 The authors declare no competing interests.

302

303

304 **DATA AVAILABILITY**

305 The authors declare that the data supporting the findings of this study are available within
306 the paper and its supplementary information files. Plasmid sequences are available upon
307 request.

308

309 **MATERIALS AND METHODS**

310

311 **Plasmid construction**

312 A repeat-variable di-residue (RVD) domain specifically targeting the 5'-
313 CTCTGCGCCTGCGCCGGCGC-3' sequence within the 29 bp repeat consensus sequence
314 was designed using TAL Effector Targeter⁴³. Variable numbers of the target 20 bp
315 sequence are identified within the most distal 3 kb of 20 subtelomeres according to a
316 complete clone-based assembly of human subtelomeric regions⁴⁴. A 3560 bp DNA
317 fragment corresponding to a complete TALE module comprising the designed RVD
318 followed by an SV40 nuclear localization signal and a human influenza hemagglutinin (HA)
319 tag was synthesized at GenScript. The fragment was cloned into KpnI/ApaI digested a
320 pcDNA5-FRT-TO plasmid (ThermoFisher Scientific) downstream of a doxycycline-
321 inducible CMV promoter (unfused T-TALE). The obtained plasmid was digested with ClaI
322 and EcoRV and ligated to a 429 bp fragment comprising the Enhanced Repressor Domain
323 and synthesized at GenScript (SID4X T-TALE). Plasmid sequences are available upon
324 request.

325

326 **Cell culture procedures**

327 T-TALE expressing U2OS cells were generated by FRT-mediated integration of unfused T-
328 TALE and SID4X T-TALE plasmids into T-REx™-U2OS cells expressing the TetR protein
329 (ThermoFisher Scientific). Clonal selection was performed by plating cells at low dilution
330 in high glucose DMEM, GlutaMAX (Thermo Fisher Scientific) supplemented with 10%
331 tetracycline-free fetal bovine serum (Pan BioTech), 100 U/ml penicillin-streptomycin
332 (Thermo Fisher Scientific) and 200 µg/ml hygromycin B (VWR). Individual clones were
333 manually picked and expanded in the same medium. For T-TALE induction, 50 ng/ml
334 doxycycline (dox; Sigma-Aldrich) was added to the culture medium devoid of hygromycin
335 B for 24-72 hours; for longer induction times, dox was refreshed every 72 hours.
336 Mycoplasma contaminations were tested using the LookOut Mycoplasma PCR Detection
337 Kit (Sigma-Aldrich) according to the manufacturer's instructions. When indicated, cells
338 were treated with 1 µM camptothecin (Sigma-Aldrich) for 6 h.

339

340 **Fluorescence-activated cell sorting (FACS)**

341 Cells were trypsinized and pelleted by centrifugation at 500 g at 4°C for 5 min. Cell pellets
342 were fixed in 70% ethanol at -20°C for 30 min and treated with 25 µg/ml RNaseA (Sigma-
343 Aldrich) in 1x PBS at 37°C for 20 min. Cells were then centrifuged as above and pellets
344 washed in 1x PBS and stained with 20 µg/ml propidium iodide (Sigma-Aldrich) in 1x PBS
345 at 4°C for 10 min. Flow cytometry was performed on a BD Accuri C6 (BD Biosciences). Data
346 were analyzed using FlowJo software.

347

348 **Western blotting**

349 Cells were trypsinized and pelleted by centrifugation at 500 g at 4°C for 5 min. Pellets
350 were resuspended in 2x lysis buffer (4% SDS, 20% Glycerol, 120 mM Tris-HCl pH 6.8),
351 boiled at 95°C for 5 min and centrifuged at 1600 g at 4°C for 10 min. Supernatants were
352 recovered and protein concentrations determined by Lowry assay using bovine serum
353 albumin (Sigma-Aldrich) as a standard. 30 µg of proteins were mixed with 0.004%
354 Bromophenol blue and 1% β-Mercaptoethanol (Sigma-Aldrich), incubated at 95°C for 5
355 min, separated in polyacrylamide gels, and transferred to nitrocellulose membranes
356 (Maine Manufacturing, LLC) using a Trans-Blot SD Semi-Dry Transfer Cell apparatus (Bio-
357 Rad). The following primary antibodies were used: a rabbit monoclonal anti-HA (Cell
358 Signaling, 3724; 1:1000 dilution), a rabbit polyclonal anti-RAP1 (Bethyl, A300-306A;
359 1:2000), a mouse monoclonal anti-PCNA (Santa Cruz Biotechnology, sc-56; 1:10000), a
360 rabbit polyclonal anti-TRF2 (Novus Biologicals, NB110-57130; 1:2000), a mouse
361 monoclonal anti-POLD3 (Novus Biologicals, H00010714-M01; 1:500), a mouse
362 monoclonal anti-ACTB (Santa Cruz Biotechnology, sc-47778; 1:2000), a mouse
363 monoclonal anti-PML (Santa Cruz Biotechnology, sc-966; 1:500), a rabbit polyclonal anti-
364 pSer33 (Bethyl, A300-246A; 1:2000), a rabbit polyclonal anti-RPA32 (Bethyl, A300-244A;
365 1:1000), a rabbit polyclonal anti-LMB1 (GeneTex, GTX103292S; 1:5000), a rabbit
366 polyclonal anti-H3 (Santa Cruz Biotechnology, sc-10809; 1:4000), a mouse monoclonal
367 anti-γH2AX (Millipore, 05-636, 1:2000), a rabbit polyclonal anti-H3 (Santa Cruz
368 Biotechnology, sc-10809; 1:4000). Secondary antibodies were HRP-conjugated goat anti-

369 mouse and anti-rabbit IgGs (Bethyl Laboratories, A90-116P and A120-101P; 1:3000).
370 Signals were acquired using an Amersham 680 blot and gel Imager.

371

372 **DNA fluorescence *in situ* hybridization (FISH) and chromosome orientation FISH (CO-**
373 **FISH)**

374 Metaphase spreads were prepared by incubating cells with 200 ng/ml Colchicine (Sigma-
375 Aldrich) for 5 h. Mitotic cells were harvested by shake-off and incubated in 0.075 M KCl at
376 37 °C for 10 min. Chromosomes were fixed in ice-cold methanol/acetic acid (3:1) and
377 spread on glass slides. Slides were treated with 20 µg/ml RNase A (Sigma-Aldrich), in 1x
378 PBS at 37 °C for 1 h, fixed in 4% formaldehyde (Sigma-Aldrich) in 1x PBS for 2 min, and
379 treated with 70 µg/ml pepsin (Sigma-Aldrich) in 2 mM glycine, pH 2 (Sigma-Aldrich) at
380 37°C for 5 min. Slides were fixed again with 4% formaldehyde in 1x PBS for 2 min,
381 incubated subsequently in 70%, 90% and 100% ethanol for 5 min each, and air-dried. A C-
382 rich telomeric PNA probe (5'-Cy3-OO-CCCTAACCTAACCTAA-3'; Panagene) diluted in
383 hybridization solution (10 mM Tris-HCl pH 7.2, 70% formamide, 0.5% blocking solution
384 (Roche)) was applied onto the slides followed by incubation at 80°C for 5 min and at room
385 temperature for 2 h. Slides were washed twice in 10 mM Tris-HCl pH 7.2, 70% formamide,
386 0.1% BSA and three times in 0.1 M Tris-HCl pH 7.2, 0.15 M NaCl, 0.08% Tween-20 at room
387 temperature for 10 min each. For CO-FISH, cells were incubated with BrdU:BrdC (3:1, final
388 concentration 10 µM; Sigma-Aldrich) for 16 h prior to metaphase preparation as above.
389 Chromosomes were spread on glass slides, treated with RNaseA as above and incubated
390 with 10 µg/ml Hoechst 33258 (Invitrogen) in 2x SSC for 15 min at room temperature.
391 Slides were exposed to 365-nm ultraviolet light using a Stratagene Stratalinker 1800 UV
392 irradiator set to 5400 Joules, and incubated with 3U/µl Exonuclease III (New England
393 Biolabs) at 37°C for 30 min. Subsequent hybridizations were performed in 30% formamide,
394 2x SSC for 3h at room temperature using first a C-rich telomeric LNA probe (5'-6-FAM-
395 CCCTAACCTAACCTAA-3'; Exiqon) and then a G-rich telomeric LNA probe (5'-TYE563-
396 TTAGGGTTAGGGTTAGGG; Exiqon). After each hybridization, slides were washed three
397 times in 2x SSC at room temperature for 10 min. Both for FISH and CO-FISH, DNA was
398 counterstained with 100 ng/ml DAPI (Sigma-Aldrich) in 1x PBS and slides were mounted

399 in Vectashield (Vectorlabs). Images were acquired with a Zeiss Cell Observer equipped
400 with a cooled AxioCam 506 m camera and a 63X/1.4NA oil DIC M27 PlanApo N objective.
401 Image analysis was performed using ImageJ and Photoshop software.

402

403 **EdU incorporation and detection at telomeres**

404 Cells grown on coverslips were incubated in medium containing 2 mM Thymidine (Sigma-
405 Aldrich) for 21 h before replacement with fresh dox-containing medium. After 4 h, 10 μ M
406 RO-3306 (Selleckchem) was added and 18 h later 10 μ M EdU (Thermo Fisher Scientific)
407 was added to the culture medium, followed by a 2.5 h incubation. Cells were hybridized
408 as for DNA FISH, washed twice with 1x PBS and EdU was detected using the Click-iT EdU
409 Alexa Fluor 488 Imaging Kit (Thermo Fisher Scientific) according to the manufacturer's
410 instructions. DNA was counterstained with 100 ng/ml DAPI in 1x PBS and coverslips were
411 mounted on slides in Vectashield. Image acquisition and analysis were as for DNA FISH.

412

413 **Indirect immunofluorescence (IF)**

414 For HA detection, cells grown on coverslips were incubated in 100% Methanol (Merk) at
415 -20°C for 15 min. For all other IF experiments, cells were incubated in CSK buffer (100 mM
416 NaCl, 300 mM sucrose, 3 mM MgCl_2 , 0.5% Triton X-100, 10 mM PIPES pH 7) for 7 min on
417 ice, fixed with 4% formaldehyde (Sigma-Aldrich) in 1x PBS for 10 min and permeabilized
418 again with CSK buffer for 5 min. Fixed cells were incubated in blocking solution (0.5% BSA,
419 0.1% Tween-20 in 1x PBS) for 1 h followed by incubation in blocking solution containing
420 primary antibodies for 1 h, three washes with 0.1% Tween-20 in 1x PBS for 10 min each,
421 and incubation with secondary antibodies diluted in blocking solution for 50 min. For
422 combined IF and DNA FISH, cells were again fixed with 4% formaldehyde in 1x PBS for 10
423 min, washed three times with 1x PBS, incubated in 10 mM Tris-HCl pH 7.2 for 5 min and
424 then denatured and hybridized with a PNA probe (5'-AF568-OO-CCCTAACCTAACCTAA-
425 3'; Panagene) as for DNA FISH. DNA was counterstained with 100 ng/ml DAPI in 1x PBS or
426 in 0.1 M Tris-HCl pH 7.2, 0.15 M NaCl, 0.08% Tween-20. Coverslips were mounted on
427 slides in Vectashield. The following primary antibodies were used: a rabbit monoclonal
428 anti-HA (Cell Signaling, 3724; 1:1000 dilution), a rabbit polyclonal anti-RAP1 (Bethyl,

429 A300-306A; 1:2000), a mouse monoclonal anti-TRF2 (Millipore, 05-521; 1:2000), a mouse
430 monoclonal anti-POLD3 (Novus Biologicals, H00010714-M01; 1:500), a mouse
431 monoclonal anti-PML (Santa Cruz Biotechnology, sc-966; 1:500), a rabbit polyclonal anti-
432 pSer33 (Bethyl, A300-246A; 1:2000), a rabbit polyclonal anti-RPA32 (Bethyl, A300-244A;
433 1:1000), a mouse monoclonal anti- γ H2AX (Millipore, 05-636; 1:2000). Secondary
434 antibodies were Alexa Fluor 568-conjugated donkey anti-rabbit IgGs (Thermo Fisher
435 Scientific, A10042; 1:1000) and Alexa Fluor 488-conjugated donkey anti-mouse IgGs
436 (Thermo Fisher Scientific, A21202; 1.1000). Image acquisition and analysis were as for
437 DNA FISH.

438

439 **Chromatin immunoprecipitation (ChIP)**

440 Cells were harvested by trypsinization, centrifuged at 500 g at 4°C for 5 min and
441 resuspended in 1% formaldehyde (Sigma-Aldrich) for 20 min at room temperature,
442 followed by quenching with 125 mM glycine (VWR) for 5 min. Cross-linked cells were
443 centrifuged as above and pellets were resuspended in ChIP lysis buffer (1% SDS, 10 mM
444 EDTA, 50 mM Tris-HCl pH 8), sonicated using a Bioruptor apparatus (Diagenode) and
445 centrifuged at 16000 g for 10 minutes at 4°C. 1 mg of lysate was diluted in ChIP dilution
446 buffer (150 mM NaCl, 20 mM Tris-HCl pH 8, 1% Triton X-100, 2 mM EDTA) and incubated
447 with 2 μ g of a rabbit monoclonal anti-HA antibody (Cell Signaling, 3724) for 2 h at room
448 temperature. Immunocomplexes were isolated by incubation with Protein A/G PLUS-
449 Agarose beads (Santa Cruz Biotechnology) at 4°C overnight on a rotating wheel. Beads
450 were washed 4 times in ChIP wash buffer (150 mM NaCl, 20 mM Tris-HCl pH 8, 1% Triton
451 X-100, 0.1% SDS, 2 mM EDTA) and once in ChIP final wash buffer (500 mM NaCl, 20 mM
452 Tris-HCl pH 8, 1% Triton X-100, 0.1% SDS, 2 mM EDTA). Beads were incubated in ChIP
453 elution buffer (1% SDS, 100 mM NaHCO₃) containing 40 μ g/ml RNase A (Sigma-Aldrich)
454 for 1 hour at 37°C and DNA was extracted using the Wizard SV gel and PCR cleanup system
455 (Promega). Input and immunoprecipitated DNA was subjected to quantitative PCR using
456 the oligonucleotides shown in Table 1. QPCRs were performed using the iTaq Universal
457 SYBR Green Supermix (Bio-Rad) on a Rotor-Gene Q (Qiagen) instrument with a 2-step

458 program (45 cycles of denaturation at 95°C for 15 sec, annealing and extension at 60°C
459 for 30 sec). Data analysis was performed using the Rotor-Gene 6000 Series Software 1.7.

460

461 **Reverse transcription and quantitative PCR**

462 Total RNA was isolated using the TRIzol reagent (Thermo Fisher Scientific) followed by
463 chloroform extraction and treated three times with 3.5 U of DNaseI (Qiagen) for 45
464 minutes at room temperature. 5 µg of RNA were reverse transcribed with 0.5 µM TeloR
465 and 0.05 µM ActinR oligonucleotides (Table 1) and Superscript III (Thermo Fisher
466 Scientific) according to the manufacturer's instructions. Quantitative PCRs were
467 performed and analyzed as for ChIP using the oligonucleotides shown in Table 1. Actin
468 values were used as normalizers.

469

470 **C-circle assay**

471 Genomic DNA was isolated by phenol:chloroform extraction and treatment with 40 µg/ml
472 RNaseA (Sigma-Aldrich), followed by ethanol precipitation. Reconstituted DNA was
473 digested with HinfI and RsaI (New England Biolabs) and again purified by
474 phenol:chloroform extraction. 500 ng of digested DNA were incubated with 7.5 U of phi29
475 DNA polymerase (New England Biolabs) in presence of dATP, dTTP and dGTP (1 mM each)
476 at 30°C for 8 h, followed by heat-inactivation at 65°C for 20 min. Amplification products
477 were dot-blotted onto nylon membranes (GE Healthcare) and hybridized at 55°C
478 overnight with a double-stranded telomeric probe (Telo2 probe), radioactively labeled
479 using Klenow fragment (New England Biolabs) and [α -32P]dCTP. Post-hybridization
480 washes were twice in 2x SSC, 0.2% SDS for 20 min and once in 0.2x SSC, 0.2% SDS for 30
481 min at 50°C. Radioactive signals were detected using a Typhoon FLA 9000 imager (GE
482 Healthcare) and quantified using ImageJ software.

483

484 **Statistical analysis**

485 For direct comparison of two groups, we employed a paired two-tailed student's t-test
486 using Microsoft Excel or a nonparametric two-tailed Mann-Whitney U test using
487 GraphPad Prism. Values are indicated as: * $P < 0.05$, ** $P < 0.005$, *** $P < 0.001$,
488 **** $P < 0.0001$.

489 **REFERENCES**

- 490 1. Azzalin, C.M. & Lingner, J. Telomere functions grounding on TERRA firma. *Trends Cell*
491 *Biol* **25**, 29-36 (2015).
- 492 2. Nergadze, S.G. *et al.* CpG-island promoters drive transcription of human telomeres.
493 *RNA* **15**, 2186-94 (2009).
- 494 3. Azzalin, C.M., Reichenbach, P., Khoraiuli, L., Giulotto, E. & Lingner, J. Telomeric repeat
495 containing RNA and RNA surveillance factors at mammalian chromosome ends.
496 *Science* **318**, 798-801 (2007).
- 497 4. Porro, A., Feuerhahn, S., Reichenbach, P. & Lingner, J. Molecular dissection of
498 telomeric repeat-containing RNA biogenesis unveils the presence of distinct and
499 multiple regulatory pathways. *Mol Cell Biol* **30**, 4808-17 (2010).
- 500 5. Moravec, M. *et al.* TERRA promotes telomerase-mediated telomere elongation in
501 *Schizosaccharomyces pombe*. *EMBO Rep* **17**, 999-1012 (2016).
- 502 6. Cusanelli, E., Romero, C.A. & Chartrand, P. Telomeric noncoding RNA TERRA is
503 induced by telomere shortening to nucleate telomerase molecules at short telomeres.
504 *Mol Cell* **51**, 780-91 (2013).
- 505 7. Chu, H.P. *et al.* TERRA RNA Antagonizes ATRX and Protects Telomeres. *Cell* **170**, 86-
506 101 e16 (2017).
- 507 8. Arora, R. *et al.* RNaseH1 regulates TERRA-telomeric DNA hybrids and telomere
508 maintenance in ALT tumour cells. *Nat Commun* **5**, 5220 (2014).
- 509 9. Silva, B. *et al.* FANCM limits ALT activity by restricting telomeric replication stress
510 induced by deregulated BLM and R-loops. *Nat Commun* **10**, 2253 (2019).
- 511 10. Pfeiffer, V., Crittin, J., Grolimund, L. & Lingner, J. The THO complex component Thp2
512 counteracts telomeric R-loops and telomere shortening. *EMBO J* **32**, 2861-71 (2013).
- 513 11. Balk, B. *et al.* Telomeric RNA-DNA hybrids affect telomere-length dynamics and
514 senescence. *Nat Struct Mol Biol* **20**, 1199-205 (2013).
- 515 12. Lee, Y.W., Arora, R., Wischnewski, H. & Azzalin, C.M. TRF1 participates in
516 chromosome end protection by averting TRF2-dependent telomeric R loops. *Nat*
517 *Struct Mol Biol* **25**, 147-153 (2018).
- 518 13. Deng, Z., Norseen, J., Wiedmer, A., Riethman, H. & Lieberman, P.M. TERRA RNA
519 binding to TRF2 facilitates heterochromatin formation and ORC recruitment at
520 telomeres. *Mol Cell* **35**, 403-13 (2009).
- 521 14. Feretzaki, M., Renck Nunes, P. & Lingner, J. Expression and differential regulation of
522 human TERRA at several chromosome ends. *RNA* **25**, 1470-1480 (2019).
- 523 15. Episkopou, H. *et al.* Alternative Lengthening of Telomeres is characterized by reduced
524 compaction of telomeric chromatin. *Nucleic Acids Res* **42**, 4391-405 (2014).
- 525 16. Arnoult, N., Van Beneden, A. & Decottignies, A. Telomere length regulates TERRA
526 levels through increased trimethylation of telomeric H3K9 and HP1alpha. *Nat Struct*
527 *Mol Biol* **19**, 948-56 (2012).
- 528 17. Sagie, S. *et al.* Telomeres in ICF syndrome cells are vulnerable to DNA damage due to
529 elevated DNA:RNA hybrids. *Nat Commun* **8**, 14015 (2017).


- 530 18. Aguado, J. *et al.* Inhibition of DNA damage response at telomeres improves the
531 detrimental phenotypes of Hutchinson-Gilford Progeria Syndrome. *Nat Commun* **10**,
532 4990 (2019).
- 533 19. Porro, A. *et al.* Functional characterization of the TERRA transcriptome at damaged
534 telomeres. *Nature Communications* **5**(2014).
- 535 20. Deng, Z. *et al.* A role for CTCF and cohesin in subtelomere chromatin organization,
536 TERRA transcription, and telomere end protection. *EMBO J* **31**, 4165-78 (2012).
- 537 21. Koskas, S. *et al.* Heat shock factor 1 promotes TERRA transcription and telomere
538 protection upon heat stress. *Nucleic Acids Res* **45**, 6321-6333 (2017).
- 539 22. Diman, A. *et al.* Nuclear respiratory factor 1 and endurance exercise promote human
540 telomere transcription. *Sci Adv* **2**, e1600031 (2016).
- 541 23. Montero, J.J. *et al.* TERRA recruitment of polycomb to telomeres is essential for
542 histone trymethylation marks at telomeric heterochromatin. *Nat Commun* **9**, 1548
543 (2018).
- 544 24. Montero, J.J., Lopez de Silanes, I., Grana, O. & Blasco, M.A. Telomeric RNAs are
545 essential to maintain telomeres. *Nat Commun* **7**, 12534 (2016).
- 546 25. Min, J., Wright, W.E. & Shay, J.W. Alternative Lengthening of Telomeres Mediated by
547 Mitotic DNA Synthesis Engages Break-Induced Replication Processes. *Mol Cell Biol*
548 **37**(2017).
- 549 26. Sobinoff, A.P. & Pickett, H.A. Alternative Lengthening of Telomeres: DNA Repair
550 Pathways Converge. *Trends Genet* **33**, 921-932 (2017).
- 551 27. Dilley, R.L. *et al.* Break-induced telomere synthesis underlies alternative telomere
552 maintenance. *Nature* **539**, 54-58 (2016).
- 553 28. Roumelioti, F.M. *et al.* Alternative lengthening of human telomeres is a conservative
554 DNA replication process with features of break-induced replication. *EMBO Rep* **17**,
555 1731-1737 (2016).
- 556 29. Zhang, J.M., Yadav, T., Ouyang, J., Lan, L. & Zou, L. Alternative Lengthening of
557 Telomeres through Two Distinct Break-Induced Replication Pathways. *Cell Rep* **26**,
558 955-968 e3 (2019).
- 559 30. Pan, X. *et al.* FANCM suppresses DNA replication stress at ALT telomeres by disrupting
560 TERRA R-loops. *Sci Rep* **9**, 19110 (2019).
- 561 31. Lu, R. *et al.* The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening
562 of telomeres (ALT). *Nat Commun* **10**, 2252 (2019).
- 563 32. Domingues-Silva, B., Silva, B. & Azzalin, C.M. ALternative Functions for Human
564 FANCM at Telomeres. *Front Mol Biosci* **6**, 84 (2019).
- 565 33. Arora, R. & Azzalin, C.M. Telomere elongation chooses TERRA ALternatives. *RNA Biol*,
566 0 (2015).
- 567 34. Mussolino, C. & Cathomen, T. TALE nucleases: tailored genome engineering made
568 easy. *Curr Opin Biotechnol* **23**, 644-50 (2012).
- 569 35. Flynn, R.L. *et al.* Alternative lengthening of telomeres renders cancer cells
570 hypersensitive to ATR inhibitors. *Science* **347**, 273-7 (2015).
- 571 36. Garcia-Muse, T. & Aguilera, A. R Loops: From Physiological to Pathological Roles. *Cell*
572 **179**, 604-618 (2019).

- 573 37. Sobinoff, A.P. *et al.* BLM and SLX4 play opposing roles in recombination-dependent
574 replication at human telomeres. *EMBO J* **36**, 2907-2919 (2017).
- 575 38. Verma, P. *et al.* RAD52 and SLX4 act nonepistatically to ensure telomere stability
576 during alternative telomere lengthening. *Genes Dev* **33**, 221-235 (2019).
- 577 39. Pepe, A. & West, S.C. MUS81-EME2 promotes replication fork restart. *Cell Rep* **7**,
578 1048-55 (2014).
- 579 40. Zeng, S. *et al.* Telomere recombination requires the MUS81 endonuclease. *Nat Cell*
580 *Biol* **11**, 616-23 (2009).
- 581 41. Panier, S. *et al.* SLX4IP Antagonizes Promiscuous BLM Activity during ALT
582 Maintenance. *Mol Cell* **76**, 27-43 e11 (2019).
- 583 42. Graf, M. *et al.* Telomere Length Determines TERRA and R-Loop Regulation through
584 the Cell Cycle. *Cell* **170**, 72-85 e14 (2017).
- 585 43. Doyle, E.L. *et al.* TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector
586 design and target prediction. *Nucleic Acids Res* **40**, W117-22 (2012).
- 587 44. Stong, N. *et al.* Subtelomeric CTCF and cohesin binding site organization using
588 improved subtelomere assemblies and a novel annotation pipeline. *Genome Res* **24**,
589 1039-50 (2014).

590

591 **FIGURES**

592




593

594

595 **Figure 1: Development and validation of T-TALEs.** (a) Schematic representation of T-
 596 TALEs. The RVD domain recognizing the indicated nucleotides within the 29 bp repeat
 597 consensus sequence is represented by grey rounded rectangles. NLS: nuclear localization
 598 signal; SID4X: four transcription repressor domains of the mSIN3 interaction domain; HA:
 599 human influenza hemagglutinin tag. (b) Quantification of anti-HA ChIPs in the indicated
 600 cell lines treated with dox for 24 hours. QPCRs were performed with oligonucleotides
 601 amplifying subtelomeric regions from chromosome ends containing or devoid of 29 bp
 602 repeats (29 bp+ and 29 bp-, respectively). For 29 bp+ subtelomeres, two oligonucleotide
 603 pairs placed at different distances from the 29 bp array were used and are indicated as N
 604 (near) and F (far). Control qPCR were performed with oligonucleotides amplifying
 605 sequences from a unique region of the X chromosome centromere (Xcen), alphoid DNA
 606 (Alph) and beta Actin (ACTB) and U6 gene loci. Values are graphed as input DNA found in
 607 the corresponding ChIP samples normalized to U2OS parental samples. Bars and error
 608 bars are means and SEMs from 3 independent experiments. Circles are single data points.
 609 (c) RT-qPCR quantifications of TERRA transcripts from 29 bp+ and 29 bp- chromosome
 610 ends in the indicated cell lines, treated with dox for 24 hours or left untreated. Values are
 611 graphed normalized to -dox. Bars and error bars are means and SEMs from 2 independent
 612 experiments for 9pXq and 20q and from 4 independent experiments for the remaining
 613 chromosome ends. Circles are single data points. *P* values were calculated with a two-
 614 tailed Student's *t*-test. **P* < 0.05, ***P* < 0.005, ****P* < 0.001, *****P* < 0.0001.


615



616
617


618 **Figure 2: TERRA transcription inhibition alleviates telomere instability.** (a) Examples of
619 RPA32, pSer33 or γH2AX IF (green) combined with telomeric DNA FISH (teloDNA) or TRF2
620 IF (red). DAPI stained DNA is in blue. The indicated cell lines were treated with dox for 24
621 hours for RPA32 and pSer33 or 72 hours for γH2AX. Arrowheads in the merge panels point
622 to co-localization events. Scale bar: 5 μm. (b) Box plots of the 10-90 percentile of co-
623 localization events per nucleus in experiments as in a. Central lines are medians. A total
624 of at least 300 nuclei from three independent experiments were analyzed for each sample.
625 *P* values were calculated with a Mann-Whitney *U* test. ***P* < 0.005, ****P* < 0.001, *****P*
626 < 0.0001.

627



628
629

Figure 3: TERRA transcription inhibition alleviates ALT activity. (b) Left and right panels: examples of PML or POLD3 IF (green) combined with telomeric DNA FISH (teloDNA) or RAP1 IF (red). Middle panels: examples of EdU detection (green) combined with telomeric DNA FISH (red). DAPI stained DNA is in blue. The indicated cell lines were treated with dox for 24 hours for PML or for 24.5 hours for POLD3 and EdU (G2/M synchronized cells, see methods for details). Arrowheads in the merge panels point to co-localization events. Scale bar: 5 μ m. **(b)** Box plots of the 10-90 percentile of co-localization events per nucleus in experiments as in **a**. Central lines are medians. A total of at least 300 nuclei from three independent experiments were analyzed for each sample. P values were calculated with a Mann-Whitney U test. * $P < 0.05$, ** $P < 0.005$, **** $P < 0.0001$.



640

641

642

643

644

645

646

647

648

649

650

651

652


653

654

655

656

Figure 4: TERRA transcription inhibition diminishes the frequencies of DLead chromosome ends. (a) Schematic representation of telomeric features scored in CO-FISH experiments. DLead: sister telomeres with 2 leading and one lagging strand signals; DLagg: sister telomeres with 2 lagging and one leading strand signals; TSCEs: telomeric sister chromatid exchanges. (b) Examples of CO-FISH on metaphases from *sid4* cells treated with dox for 72 hours. Leading and lagging strand telomeres are in red and green, respectively; DAPI stained DNA is in blue. Red arrowheads point to DLeads, green arrowheads to DLaggs and yellow arrows to TSCEs. A chromosome with one DLead and one TSCE at its two opposite ends is shown at higher magnification at the bottom. (c) Quantifications of telomeric features in CO-FISH experiments as in b. A total of at least 2538 chromosomes from 3 independent experiments were analyzed for each condition. Bars and error bars are means and SEMs. Circles are single data points. *P* values were calculated with a two-tailed Student's *t*-test. ****P* < 0.001. (d) Speculative model for DLead generation. Scissors represent structure specific endonucleases. See Discussion for details.



657

658

659 **Figure 5: TERRA transcription inhibition leads to accumulation of TFEs. (a)** Examples of

660 telomeric DNA FISH on metaphases from the indicated cell lines treated with dox for 0 or

661 9 days (d). Telomeric repeat DNA is in red, DAPI-stained chromosomal DNA in blue. White

662 arrowheads point to chromosome arms with TFEs. **(b)** Box plots of the 10-90 percentile

663 of TFEs per metaphase in experiments as in **a**. Central lines are medians. Cells were

664 harvested at the indicated days of dox treatment. A total of at least 2761 chromosomes

665 from 2 or 3 independent experiments were analyzed for each condition. *P* values were

666 calculated with a Mann-Whitney *U* test. **P* < 0.05, ***P* < 0.005, *****P* < 0.0001.

667

668
669

Table 1: oligonucleotides used in this study

Name	Oligo sequence (5'-3')	Genomic locus	Application
10qnearF	TAGCACACACCCGGAGAGCA	10q subtelomere	ChIP qPCR
10qnearR	CTCTGCTCCGCTTCGCAAT	10q subtelomere	ChIP qPCR
10qfarF	GAATCCTGCGCACCGAGAT	10q subtelomere	ChIP qPCR
10qfarR	CTGCACTTGAACCCTGCAATAC	10q subtelomere	ChIP qPCR
15qnearF	GCCTTTGCGACGGCGGAG	15q subtelomere	ChIP qPCR
15qnearR	CGCCTTCGAGTACCACC	15q subtelomere	ChIP qPCR
15qfarF	CAGCGAGATTCTCCAAGCTAAG	15q subtelomere	ChIP qPCR
15qfarR	AACCCTAACACATGAGCAACG	15q subtelomere	ChIP qPCR
XYqnearF	TGTCCTCTGCACAGATTTGCG	XqYq subtelomere	ChIP qPCR
XYqnearR	TCTGTGCTTAGGGGAATGCT	XqYq subtelomere	ChIP qPCR
XYqfarF	CACCCTCACCTAAGCACAT	XqYq subtelomere	ChIP qPCR
XYqfarR	AAGCAAAAGCCCCTCTGAAT	XqYq subtelomere	ChIP qPCR
XYpF	GCAAAGAGTGAAAGAACGAAGCTT	XpYp subtelomere	ChIP qPCR TERRA RT-qPCR
XYpR	CCCTCTGAAAGTGGACCAATCA	XpYp subtelomere	ChIP qPCR TERRA RT-qPCR
12qF	ATTTCCCGTTTTCCACACTGA	12q subtelomere	ChIP qPCR TERRA RT-qPCR
12qR	CTGTTTGCAGCGCTGAATATTC	12q subtelomere	ChIP qPCR TERRA RT-qPCR
XcenFwd	GTGACGATGGAGTTTAACTCAGGG	X centromere	ChIP qPCR
XcenRev	GCTTTCCGTTTCAAGTTATGGGAAGG	X centromere	ChIP qPCR
AlphoidF	CTCAGAAACTTCTTTGTGATGTGT	Aplhoid DNA	ChIP qPCR
AlphoidR	TATTCCTTTTGGAACGAAGGC	Aplhoid DNA	ChIP qPCR
ActF	TCCCTGGAGAAGAGCTACGA	Beta Actin gene	ChIP qPCR TERRA RT-qPCR
ActR	AGCACTGTGTTGGCGTACAG	Beta Actin gene	ChIP qPCR TERRA RT-qPCR
U6F	CTCGCTTCGGCAGCACATATA	U6 gene	ChIP qPCR
U6R	GGAACGCTTACGAATTTGCGT	U6 gene	ChIP qPCR
9pXYqF	TTCCGCACTGAACCGCTCTAA	9p and XYq subtelomere	TERRA RT-qPCR
9pXYqR	GCAGCCATGAATAATCAAGGT	9p and XYq subtelomere	TERRA RT-qPCR
10qF	GAATCCTGCGCACCGAGAT	10q subtelomere	TERRA RT-qPCR
10qR	CTGCACTTGAACCCTGCAATAC	10q subtelomere	TERRA RT-qPCR
15qF	CAGCGAGATTCTCCAAGCTAAG	15q subtelomere	TERRA RT-qPCR
15qR	AACCCTAACACATGAGCAACG	15q subtelomere	TERRA RT-qPCR
16pF	TGTGTTTCAACGCTGCAACTG	16q subtelomere	TERRA RT-qPCR
16pR	AGTTAGAACC GTTCAGTGTG	16q subtelomere	TERRA RT-qPCR
10pF	CCTTCTAACTGGACTCTGAC	10p subtelomere	TERRA RT-qPCR
10pR	GCCACAGCGACGGTAAATAA	10p subtelomere	TERRA RT-qPCR
20qF	GCAGCTTTCTCAGCACAC	20q subtelomere	TERRA RT-qPCR
20qR	TTTGTTCACTGTGCGATGCG	20q subtelomere	TERRA RT-qPCR
TeloR	(CCCTAA) ₅	Telomeric repeats	TERRA RT-qPCR

670

Supplementary information for:

**TERRA transcription destabilizes telomere integrity to initiate break-induced replication
in human ALT cells.**

Bruno Silva^{1,3}, Rajika Arora^{1,2,3} and Claus M. Azzalin^{1,4,*}

SUPPLEMENTARY FIGURES




Figure S1: Expression of T-TALEs and endogenous proteins used in this study. (a) Examples of anti-HA tag IF (green) in the indicated cell lines treated with dox for 24 hours or left untreated. DAPI stained DNA is in blue. Scale bar: 10 μ m. **(b)** Western blot analysis of the indicated cell lines treated with dox as in **a**. Red lines separate signals from different membranes. Beta actin (ACTB), PCNA, Lamin B1 (LMB1) and histone H3 serve as loading control. Numbers on the left are molecular weights in in kDa. CPT: camptothecin.




Figure S2: Cell cycle distribution analysis of T-TALE cells. (a) FACS profiles of the indicated propidium iodide (PI)-stained cells treated or not with dox and with the CDK1 inhibitor RO-3306. Cell counts (y axis) are plotted against PI intensity (x axis). Cells were harvested after 24 (asynchronous) or 24.5 (RO-3306-treated) hours of dox treatment (see methods for details). **(b)** Quantifications of experiments as in **a**. The graphs show the percentage of cells in G1, S and G2/M phases from one representative experiment.




Figure S3: TERRA transcription inhibition alleviates telomere instability and ALT activity. Examples of experiments as in Figures 2 and 3 performed in nls3 and sid4 cells. Markers and DAPI stained DNA are shown with the same colors as in Figures 2 and 3. Arrowheads in the merge panels point to co-localization events. Scale bars: 5 μ m.




Figure S4: C-circle analysis in T-TALE cells. (a) C-circle assay analysis of genomic DNA from the indicated cells treated with dox for up to 72 hours. Reaction products were dot-blotted and hybridized to a radiolabeled telomeric probe. Control reactions were performed in absence of phi29 polymerase (- Φ 29). **(b)** Quantifications of C-circle signals from experiments as in **a**. Bars and error bars are means and SEMs from 3 independent experiments. Circles are single data points.